Glucagon Receptor Agonism and Lean Mass
Retatrutide is a triple-receptor agonist that activates GIP, GLP-1, and glucagon receptors. The glucagon receptor component is of particular interest in the context of body composition, because glucagon receptor agonism increases energy expenditure and may influence the ratio of fat mass to lean mass lost during weight reduction.
What the Evidence Shows
Lean-mass preservation is an important area of obesity-treatment research. Preclinical and early clinical data suggest that glucagon receptor agonism may influence body composition favorably compared to GLP-1-only agents, but the available human evidence is limited.
Phase 2 body composition data for retatrutide indicated that approximately 30–40% of total weight lost was lean mass — a proportion broadly consistent with other GLP-1 receptor agonists and with weight loss in general. These figures are from Phase 2 and should not be extrapolated to Phase 3 populations.
The TRIUMPH-1 Phase 3 topline results did not include DEXA scan or body composition data. Definitive conclusions about lean-mass preservation in the Phase 3 population are not yet available.
Conclusion
Lean-mass preservation remains an important area of obesity-treatment research. Retatrutide's glucagon receptor activity provides a biologically interesting mechanism for continued study, but definitive conclusions about comparative lean-mass preservation require appropriate human body-composition data.
Claims that retatrutide preserves more lean mass than semaglutide or another therapy are not supported by appropriate direct comparative evidence at this time.